Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Werner Lederer

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|October 13, 2021
Regulation of ER Composition and Extent, and Putative Action in Protein Networks by ER/NE Protein TMEM147Giannis Maimaris, Andri Christodoulou, Niovi Santama, et al.
Journal of Clinical Medicine|November 27, 2019
The Scope for Thalassemia Gene Therapy by Disruption of Aberrant Regulatory ElementsPetros Patsali, Claudio Mussolino, Petros Ladas, et al.
Blood|June 20, 2015
Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapyGaryfalia Karponi, Nikoletta Psatha, Carsten Werner Lederer, et al.
Blood|September 24, 2009
Bone marrow as an alternative site for islet transplantationElisa Cantarelli, Raffaella Melzi, Alessia Mercalli, et al.
Molecular Therapy. Methods & Clinical Development|October 16, 2018
Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-ThalassemiaMaria Rosa Lidonnici, Ylenia Paleari, Francesca Tiboni, et al.
Frontiers in Genome Editing|November 19, 2025
Proceedings of the second annual meeting of GenE-HumDi (COST Action 21113)María Ortiz-Bueno, Iris Ramos-Hernández, Luis Algeciras-Jiménez, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|October 13, 2021
Regulation of ER Composition and Extent, and Putative Action in Protein Networks by ER/NE Protein TMEM147Giannis Maimaris, Andri Christodoulou, Niovi Santama, et al.
Journal of Clinical Medicine|November 27, 2019
The Scope for Thalassemia Gene Therapy by Disruption of Aberrant Regulatory ElementsPetros Patsali, Claudio Mussolino, Petros Ladas, et al.
Blood|June 20, 2015
Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapyGaryfalia Karponi, Nikoletta Psatha, Carsten Werner Lederer, et al.
Blood|September 24, 2009
Bone marrow as an alternative site for islet transplantationElisa Cantarelli, Raffaella Melzi, Alessia Mercalli, et al.
Molecular Therapy. Methods & Clinical Development|October 16, 2018
Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-ThalassemiaMaria Rosa Lidonnici, Ylenia Paleari, Francesca Tiboni, et al.
Frontiers in Genome Editing|November 19, 2025
Proceedings of the second annual meeting of GenE-HumDi (COST Action 21113)María Ortiz-Bueno, Iris Ramos-Hernández, Luis Algeciras-Jiménez, et al.
Pageof 1